Zimmer Biomet, a global medical technology leader, has announced that it signed a definitive agreement to acquire OrthoGrid Systems, a privately-held medical technology company focused on Artificial Intelligence (AI)-driven surgical guidance systems for total hip replacement. The acquisition includes OrthoGrid’s AI-powered, fluoroscopy-based surgical assistance platform Hip AI, as well as two additional FDA-cleared orthopedic applications and over 40 patents.
Surgical guidance systems often rely on CT-based imaging which can result in a backlog of CT exams and, in turn, impact operating room (OR) workflow and efficiency. Fluoroscopy-based surgical guidance is a technique that uses real-time X-ray imaging to help guide procedures and improve surgical accuracy and safety. Unlike CT scans, fluoroscopy-based systems do not require preoperative preparation, allow real-time navigation with up-to-date images and provide convenient bedside access to motion imaging.
“OrthoGrid’s AI systems address the rapidly growing market demand for fluoroscopy-based surgical guidance solutions while strengthening our portfolio of hip offerings that drive intraoperative efficiencies and improve the quality of life for patients,” said Jim Lancaster, President, Recon and Global Headquarters Executive Director at Zimmer Biomet.